Marion Mccourt Sells 1,000 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Free Report) EVP Marion Mccourt sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $934.71, for a total transaction of $934,710.00. Following the completion of the sale, the executive vice president now owns 13,789 shares in the company, valued at approximately $12,888,716.19. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Regeneron Pharmaceuticals Trading Up 0.1 %

REGN opened at $938.49 on Thursday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $684.80 and a 1-year high of $973.99. The company has a current ratio of 6.41, a quick ratio of 5.74 and a debt-to-equity ratio of 0.10. The company has a market cap of $102.25 billion, a P/E ratio of 27.01, a price-to-earnings-growth ratio of 2.83 and a beta of 0.11. The company has a fifty day moving average price of $895.01 and a two-hundred day moving average price of $838.42.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Free Report) last posted its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The firm had revenue of $3.43 billion during the quarter, compared to the consensus estimate of $3.29 billion. During the same period in the previous year, the firm posted $10.96 earnings per share. The business’s revenue was up .6% compared to the same quarter last year. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 39.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Raymond James upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $950.00 target price on the stock in a research report on Friday, November 3rd. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Thursday, November 9th. They issued a “hold” rating and a $800.00 target price on the stock. Piper Sandler raised their target price on shares of Regeneron Pharmaceuticals from $885.00 to $895.00 and gave the company an “overweight” rating in a research report on Friday, November 3rd. TD Cowen raised their target price on shares of Regeneron Pharmaceuticals from $900.00 to $1,000.00 and gave the company an “outperform” rating in a research report on Wednesday, December 6th. Finally, Morgan Stanley cut their price target on shares of Regeneron Pharmaceuticals from $915.00 to $914.00 and set an “overweight” rating on the stock in a report on Friday, November 3rd. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and nineteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $939.05.

View Our Latest Research Report on Regeneron Pharmaceuticals

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of REGN. Sunbelt Securities Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth about $25,000. Annis Gardner Whiting Capital Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth about $26,000. Fortitude Family Office LLC bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $31,000. MCF Advisors LLC increased its position in shares of Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 12 shares in the last quarter. Finally, Criterion Capital Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $37,000. 84.15% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

(Get Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Featured Articles

Insider Buying and Selling by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.